We have developed polyclonal and monoclonal antibodies against human membrane cofactor protein (MCP) to use as tools to investigate the functions of MCP on intact nucleated cells. Two human T cell lines, CEM and TALL, are CR1 -and DAF -. Pretreatment of these cell lines with M177 and polyclonal anti-MCP, which inhibit cofactor activity almost completely, resulted in effective C3 deposition immediately following addition of these cells to Mgt+/ EGTA/human sera. The deposited C3 remained expressed partly on the cell surface and most of them were gradually converted to Obi . Some of the deposited C3 were complexed with membrane proteins, since 140-and 250-kD bands became significantly accumulated on SDS-PAGE by treatment with the antibodies.
T he deposition of C3 fragments is a critical step in complement activation and subsequent complement-mediated cell damage (1) . In addition, bound C3 fragments serve as ligands for C3 receptors to participate in lymphocyte-and phagocyte-mediated cell damage (2, 3) . Therefore activation of C3 must be kept under strict control (4) . In the classical pathway, C3 can be activated only on cells where antibody deposits. In the alternative pathway, most human tissue is protected from autologous C3 deposition, whereas most foreign material is targeted by C3. The mechanism by which target sites are distinguished, however, remains to be clarified (5) . Protection of host cells from C3 attack can be explained in part by the presence of a membrane complement inhibitor, decay-accelerating factor (DAF).' Because of the absence ' Abbreviations used in this paper . DAF, decay-accelerating factor; MAC, membrane attack complex ; MCP, membrane cofactor protein; p18, an inhibitor for MAC formation, recently identified as CD59; PNH, paroxysmal nocturnal hemoglobinuria .
of DAF, paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes amplify C3 deposition (6) . In contrast, some human cell lines, including Raji and Daudi, permit deposition of human C3 on their surfaces (3, 7, 8) , despite the fact that they express DAF (3, 9) , a finding that is inexplicable. Furthermore, PNH leukocytes (10) and some human tumor cell lines (9, 11) , although they lack DAF, have only minimal ability to trigger C3 deposition. Human nucleated cells must possess another factor for regulation of C3 deposition besides DAR Membrane cofactor protein (MCP) has been shown in the fluid phase to possess C3b-binding (12) and factor I-cofactor activities (13) which may play important roles in regulation of the alternative pathway. In the present study, we demonstrated that MCP actually prevents C3 deposition on nucleated host cells . We propose the evidence that on human nucleated cells, DAF and MCP jointly engage in protection of host cells, and in some cases, either one is sufficient to prevent complement-mediated cell damage.
Materials and Methods
Proteins, Antibodies, and Cells. Human MCP (14) and C3 (15) were purified from a T cell line, HSB-2, and citrate phosphatedextrose-plasma, respectively, as previously described . Protein labeling was performed with iodogen (16) .
Rabbit polyclonal antibodies to human DAF (17) and MCP (18) wereprepared as described. Monospecificity of these antibodies was further confirmed (19) . Rabbit polyclonal antibody to human NZmicroglobulin was a gift from Dr. J. P. Atkinson (Washington University, St. Louis, MO). Mouse mAbs directed against human MCP (9, 20) and C3b/C4b receptor (CR1) (20) were produced as previouslynoted. These were purified using protein A-Sepharose (20) . Mouse mAbs against human DAF, IA10 (21) , and against p18 (22) , an inhibitor of the formation of membrane attack complex (MAC), 1F1(23), were generous gifts from Dr. T. Kinoshita (Osaka University, Osaka), and Dr. M. Tomita (Showa University, Tokyo), respectively. F(aV)2 of these antibodies were prepared by treatment with pepsin, by the method of Nisonoff (24) .
Mouse mAb to human C3bi (which is specific to a neoepitope for C3bi and C3dg, and does not react with C3, C3b, C3d, and C3c) and human C3c (which reacts with C3b, C3bi, and C3c, but not with C3d and C3dg) werepurchased from Cytotech (San Diego, CA) and Genzyme Corp. (Boston, MA), respectively. Rabbit polyclonal antibody against human C3c was from Behringwerke (Marburg, FRG).
Human T cell lines CEM and TALL, and an erythroblastoid cell line, HEL, were gifts from the Japanese Cancer Research Resources Bank (JCRA Tokyo). These were maintained in RPMI 1640 supplemented with 10% FCS (M.A. Bioproducts, Walkersville, MD) and antibiotics. Cultures were kept in a 5% CO2/95% air atmosphere at 37°C.
AssayforDeterminaam ofFuctorI-CofactorActmty A fluid phase assay system was used (13) . The buffer used in this assay was 20 mM phosphate buffer/0.02% NP-40, pH 6.2. 30 ngofMCP was preincubatedwith various concentrations ofmAbs to MCP, M75, M160, or M177, and then incubated with 0.5 jig of factor I and 10 hg of methylamine-treated fluorescent-labeled C3, f-C3(MA) or fluorescent-labeled C3b (f-0b) (25) for 3 h at 37°C. The reaction was then stopped by the addition of 10 pl of 10% SDS and 3 pi of 2-ME. The samples were analyzed by SDS-PAGE and the percent a chain cleavage of the substrates was determined by spectrofluorometry as previously described (13, 14) . The inhibitory effect of the antibodies on the cleavage off-C3b was estimated assuming that the degree of cleavage of a chains in the absence of the antibody was 100%.
Analysis of C3 Deposition on Tumor Cells. Two methods were used to assess C3 deposition. In the first method, C3 fragments deposited on the cell-surface were analyzed by flow cytometry (9) . Cells (10 6) were pretreated with about 25 pg of polyclonal antibodies to MCP or nonimmune rabbit IgG and incubated with 50 p1 of Mgz+/EGTA/human serum and 150 pl of EGTA/GVBz+ for 90 min at 37°C. As a control, EDTA/human serum was used instead of Mgt+/EGTA/sera. The cells were washed twice in PBS containing 2% BSA, and then, 3 jig ofanti-C3c or anti-C3bi mAbs were added as the fast antibody. After 45 min, thecells were again washed twice in PBS/BSA, and 5 gg ofthe second antibody [(FITClabeled-F(ab')2 of goat anti-mouse IgG ; Cappel Laboratories, Malvern, PAJ) were added . The mixtures were allowed to stand for 45 min, washed twice, and analyzed by flow cytometry. When the mAbs to MCP were used as the pretreatment reagents, rabbit polyclonal anti-C3c and FITC-labeled F(ab')2 of goat anti-rabbit IgG (Cappel Laboratories) were used as the first and second antibodies, respectively.
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The other method employed was to use SDS-PAGE and autoradiography to analyze the deposited C3 fragments (9) . Cells (106) were pretreated with 30 t+g of M177 as described above. After washing, 50 pl of "1I-labeled C3 (A2so. . -3.0) were incubated with 50 id of Mg2+/EGTAAerum or EDTA/serum, and 100 ;L1 of EGTA/GVBz+ or EDTA/GVB. The cells were washed thoroughly in PBS, solubilized with 1% NP-40/PBS containing 1 mM PMSF, 10 mM EDTA, and 25 mM iodoacetamide, pH 7.4. The samples were reduced, subjected to SDS-PAGE, and analyzed by autoradiography.
Flouwcytometry The experiments were performed at room temperature.
SDS-PAGE and Automdiography SDS-PAGE using 8% slab gels was performed by the method ofLaemmli (26) . Gels were stained, destained, dried, and then exposed at -75°C. Cronex intensifier screens (DuPont Co., Wilmington, DE) and XAR5 film (Eastman Kodak Co., Rochester, NY) were used for autoradiography (17) .
Cytolysis Assay. Cells (107) were incubated with 200 ACl of "Cr (Amersham Corp., Arlington Heights, IL) in 400 Al of RPMI for 60-120 min at 37°C (9) . Although labeling efficiency varied among the cell lines, 45,000-120,000 cpm were incorporated into 106 cells. The labeled cells were pretreated with antibodies to MCP or nonimmune IgG and incubated with 15-30% Mgz+/EGTA/serum or EIYTA/serum for 90 min at 37°C. Radioactivity in the supernatants was measured in a gamma counter.
Results
Cell Lines on Which C3 Deposition Was Induced by Treatment with Polyclonal Anti-MCP. 24 human leukemia cell lines (9) were treated with polyclonal anti-MCP and then human Mgt+/EGTAAerum . The deposited C3 was assessed with anti-human C3c or anti-human Obi mAb by flow cytometry. Two T cell lines, CEM and TALL, became C3-sensitive through treatment with anti-MCP (Fig. 1, B--D) . C3 deposited only slightly with the same treatment of most of the other cell lines, including HEL (Fig. 1 A) . The deposited C3 was expressed on the cell surface and was detected by both antibodies to C3c and Obi (Fig. 1) . As reported previously (9), little C3 was deposited on. CEM and TALL unless the cells had been treated with anti-MCP (Fig. 1) . Treatment of these cells with anti-02-microglobulin did not result in C3 deposition (not shown) . In addition, no C3 was deposited if Mgt+/EGTA/serum was substituted for EDTA serum . Therefore, the observed C3 deposition was specific for anti-MCP and the alternative complement pathway. The deposited C3 could be detected to a similar extent by both anti-0c and anti-Obi, suggesting that the main product expressed on the cells was Obi (Fig. 1 C, D) (27) .
Complement Regulatory Proteins Distributed on CEM and TALL. Using mAbs to CR1, DAF, and MCP, amounts Anti-Membrane Cofactor Protein-mediated C3 Deposition on Tumor Cells
of surface-expressed C3 regulatory proteins were assessed by flowcytometry. CR1 and DAF were not detected in CEM and TALL (Fig. 2, A, B) . The absence of CR1 and DAF in these cell lines was also supported by the protein A-rosette assay (20) and radiometric assay (9) (data not shown) . Therefore, effective C3 deposition occurred specifically on the DAF -/CR1 -cells. The level of p18, an inhibitor of the formation of MAC, was assessed in these T cell lines by flowcytometry. CEM possessed p18 whereas TALL did not (Fig . 2, C, D) . Effect of mAbs on Factor I-Cofactor Activity ofMCP and C3 Deposition on TALL. MCP acts as a cofactor for factor I to generate C3bi from C3b in the fluid phase (13, 28) . We evaluated the inhibitory activity of the mAbs towards factor I-mediated cleavage of C3b. Purified MCP (30 ng) was pretreated with varying amounts of each mAb to MCP, and incubated with factor I and f-C3b . The inhibitory efficiency of these was preincubated with M177 (lanes 2, 4, 5, and 7), and then incubated with EDTA/serum (lanes 2 and 5) or Mgt*/EGTA serum (lanes 3, 4, 6, and 7) containing 12SI-labeled purified C3 . Lane 1 is the labeled C3 used in this experiment. The arrowheads indicate C3 fragments complewd with membrane proteins. The C3 fragments were identified according to previous reports (9, 15) . BioRad molecular weight marker was used .
antibodies differed. The order of efficiency for inhibitory activity towards the factor 1-cofactor activity of MCP was M177>M75>M160 (Fig. 3) . More than 90% of MCP activity was blocked by equimolar M177 .
We next examined the effect of F(ab')2 of the mAb on C3 deposition in the T cell lines. The mAbs also had the ability to induce C3 deposition on these cells (Fig. 4) . Amounts Figure 4 . Deposition of human C3 on CEM and TALL using mAbs against MCP. CEM (A) and TALL (B) were pretreated with F(ab')2 of the mAbs antibodies to MCP, and then incubated with EDTA-of Mgt*/EGTA/serum (see the inset table) . Bound C3 was detected with polyclonal rabbit antihuman C3c (see the Table) and FITClabeled goat anti-rabbit IgG . The last antibody was added to all samples, although not shown in the of deposited C3 were compared using the three antibodies and TALL. The greatest amount was deposited on cells pretreated with M177 . The order of efficiency for induction of C3 deposition was M177>M75>M160, which is the same order as that of the inhibitory activity for factor 1-mediated C3b cleavage . Similar results were obtained with CEM (not shown). Analysis of the Deposited C3 on the DAF-/CDI -T Cells. To identify the C3 fragments deposited on M177-treated CEM and TALL, Mgt+/EGTA/serum containing 115 1-labeled C3 was incubated with the M177-treated cells. EDTA/serum and untreated cells were used as controls . The deposited fragments of 125 1-C3 were solubilized, reduced, and subjected to SDS-PAGE followed by autoradiography. In the sample with M177 and Mgt+/EGTA/serum, prominent high molecular mass bands of 250 and 140 kD together with u/u; u1, u2, and (3 chains of C3 (Fig. 5) were accumulated . Although it is unknown whether these C3 fragments were expressed on the cell surface, the results from electrophoresis suggested that C3/C3b and C3bi were the major forms detected in the NP-40 extract of the anti-MCP-treated cells (Fig. 5) .
Complement-mediated Killing of TALL which was Pretreated with the mAbs to MCP. The effect of mAbs to MCP on complement-mediated cytolysis was examined by "Cr-release assay. All antibodies, including M177, killed <10% of TALL (Fig. 6 B) . A combination of the antibodies yielded about 30% 51 Cr-release. On the other hand, polyclonal anti-MCP released >60% of the SiCr (Fig. 6 A) . CEM showed <10% release by pretreatment with either polyclonal or monoclonal antibodies (Fig. 6, A and B) .
Discussion
This paper is the first to document that MCP actually protects host cells from C3 targeting. This functional property 1677 Seya et al .
was revealed using the DAF'/CR1 -human T cell lines, which triggered efficient C3 deposition via the alternative pathway by treatment with polyclonal or monoclonal anti-MCP Little C3 was deposited on the cells that had been treated with anti-/32-microglobuhn . C3 deposition was also induced by two F(ab')2 of the mAb to MCP belonging to IgGi subclass (which lack the ability to activate complement), suggesting that C3 deposition is independent of the complementactivating effect of IgG. Of the mAbs tested, M177 caused the most efficient C3 deposition . The order of efficiency of these antibodies in the induction of C3-deposition was M177>M75>M160, which is the same as that for inhibition of MCP mediated C3b-C3bi conversion . These results suggest that the blocking of MCP cofactor activity leads directly to deposition of C3 on DAF -/CRI -cells via activation of the alternative pathway. MCP generally interacts with C3b on the same cell membrane and not with C3b on other cells, and is said to be an intrinsic factor I-cofactor protein, in contrast with the extrinsic cofactor protein, CRI (14, 28) . DAF has been characterized as an intrinsic complement regulator; although it does not serve as a cofactor, it accelerates the decay of the convertase complex (6, 29, 30) . Some human nucleated cells and cell lines become susceptible to autologous C3 if DAF is functionally blocked (11) . Ofthe three cell-associated complement regulatory molecules, DAF and MCP have now been shown to be engaged in protection of nucleated host cells from C3 attack . We favor the interpretation that the protective function of DAF and MCP is closely in conjunction with their intrinsic activities but not with their mode of inhibition . MCP is distributed on all nucleated blood cells and cell lines (18, 31) . This may partly explain the well-characterized high resistance of nucleated cells to complement attack (32) .
Extensive C3 amplification occurs on the DAF -/CR1 -T cell lines CEM and TALL ifthe MCP activity is blocked ; the C3b-accepting sites on TALL and CEM should be susceptible to MCP. This means that the DAF -/CR1 -T cell lines come to express acceptor molecules for autologous C3, thereby allowing deposition of C3b . Some of the important C3-accepting molecules are likely to be membrane proteins forming complexes with fragments of labeled C3 that migrate at 250 and 140 kD on SDS-PAGE.
It has been generally accepted that C3 deposition occurs on foreign material but not on "self" tissue since the latter does not express on its surface "activator" that can accept C3b molecules and activate the alternative pathway (33, 34) . Ifthe activator represents acceptor molecules for Cab, as Mold et al. suggested (35) , the anti-MCP-treated CEM and TALL must have activator, which accepts the initial C3b and assists in extensive amplification of C3 deposition. According to preceding work (33) (34) (35) , together with the results of our present study, most foreign cells effectively accept C3b via their activator, which eventually results in cell damage; on self cells, although most of them express activator on their surface, the C3b initially deposited on it is essentially MCPand/or DAF-sensitive, thereby preventing activation of subsequent C3, as well as its anchoring onto the cells. In other words, since most C3b deposited on molecules of human cells are not resistant to the inhibitors, they fail to amplify C3 activation . If this is the case, lack of inhibitors or a high expression of activator resistant to the action of inhibitors may be representative conditions under which C3 deposition occurs effectively on the cells. Indeed, C3 is able to deposit on human Raji cells (3, 7-9) because they express CR2 (35) which is known to evade the action of both MCP and DAF at least on B cell lines (8, 35, 36) , and on PNH erythrocytes because they lack MCP and DAF (10, 21, 30, 37) . Based on this hypothesis, autologous cells can be converted to target cells by the function of activators or by modulating the inhibitors.
Deposited C3b appears to be largely converted to C3bi, since antibodies specific to C3bi and C3c could recognize the deposited C3 fragments to a similar extent (28) . These results are only in partial agreement with those of the autoradiographic analysis of the deposited C3 (Fig. 5) , for reasons unknown. As discussed in a previous paper (9) , this discrepancy may be partly due to the fact that some C3/C3b is unexpressed, as a result of internalization . Kinetic analysis indicated that more than 30 min is required to reveal full C3bi sites (Seya, T, manuscript in preparation), suggesting that the C3 deposition and following C3b-C3bi conversion occur gradually on the'cell surface under conditions in which MCP is not functional. MCP is 50 times more active as a cofactor than factor H (13) and is known to inactivate C3b instantly, even in the fluid phase (14, 28). Most likely, this slow inactivation of the deposited C3b is not due to the surviving MCP but due to serum factor H . The fact that this slow inactivation of C3b did not impair amplification of C3 suggests the inability of the fluid phase regulatory factors to provide adequate control of cell surface activation of C3.
Many reports have suggested that efficient C3-deposition is induced on some tumor cells (7) (8) (9) (38) (39) (40) . In most cases, however, sensitizing antibody was needed for induction of C3 deposition . This means that extensive C3 activation would be required to allow acceptor molecules to deposit C3b overcoming regulatory factors. In this study, the blocking ofMCP facilitated extensive C3 deposition even without sensitizing antibodies. As shown in a previous paper (9) , most tumor cells and immature nucleated cells predominantly express MCP, but little or no CR1 . Furthermore, some lack DAF (9, 11) . Therefore, in complement-mediated cytotoxicity, a combination of anti-MCP with antibodies against tumor-associated antigens may be more effective .
It has been reported that target cells could be eliminated by CR1-mediated clearance (41), phagocytosis (2, 42, 43) , lymphocyte-mediated cytotoxicity (3, 44) , and/or C9-mediated immune-cytolysis (32) . The last has been defined traditionally as complement-mediated cytolysis . We next tested the effect of anti-MCP on complement-mediated cytolysis . Only polyclonal antibody-treated TALL were killed efficiently by complement. Monoclonal anti-MCP also induced cell destruction, but only by 30% at most. The reasons for this discrepancy between polyclonal and monoclonal antibodies remain unknown . Nucleated cells appear to have unique systems to protect against MAC formation (32, (45) (46) (47) . This may explain in part the incomplete lysis of the monoclonal anti-MCP-treated cells. CEM was barely killed by anti-MCP. This finding seems to reflect the fact that TALL, but not CEM, lacked p18 .
DAF and p18 are both phosphatidylinositol (PI)-anchored proteins (48) (49) (50) (51) . A number of tumor cell lines are reported to lack DAF, although it is unknown whether they lack p18 . A coincidental deficiency of these proteins may frequently occur on tumor cells. These DAF -/p18-cells are to be damaged only by anti-MCP treatment, which causes little or no damage to normal cells expressing DAF and p18 (Matsumoto, M., and T Seya, unpublished data). Therefore, the coincidental dysfunction of the C3 regulatory/activating system and the C9 regulatory system would lead to cell damage by autologous complement via the alternative complement cascade resulting in immune cytolysis of human nucleated cells . We have postulated that C3 deposition on autologous cells takes place more frequently than cytolysis (9) . The role and effect of the C3 fragments deposited on autologous cells, in relation to other three mechanisms of cell destruction, should prove to be of great importance in the elimination of tumor cells.
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